Is the compound identical in every case? On a molecular level it certainly is, since the term refers to one specific structure. The real question comes down to whatever else ends up inside each container and how production steps might shift those extras. Tolerance trouble with this substance plus two similar ones prompted me to look into small differences in inactive components that can arise from the freeze-drying method used. A remark in another group about factors that improve a particular source got me started on that line of thinking, though I lack the exact reference now. Whether a tiny percentage of variation can matter seems possible, given how certain individuals react strongly to minor adjustments during slow dose reductions on other medications. Community observations on that point are apparently being examined more formally by a physician abroad. My own history with mass-produced prescriptions has shown that switching manufacturing sites or inactive ingredients sometimes produces noticeable effects. Differences across batches from compounding sources will likely affect only a subset of users, and that topic stands apart from questions of fill volume or verification of contents. Everything I mentioned lacks solid references at the moment because I am tied up at the moment, yet it might point toward areas worth checking further. Separately, my research mouse showed low vitamin D, and these types of agents appear to contribute to such shortfalls, so correcting the level might improve how well the substance is handled.